Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Cabergoline, sold under the brand name Dostinex among others, is a dopaminergic medication used in the treatment of high prolactin levels, prolactinomas, Parkinson's disease, and for other indications. It is taken by mouth.
History, Applications & Research
Explore the main themes, entities and connections around Cabergoline. Start with the topic map, then use the sections below for research and deeper semantic analysis.
Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the full topic structure. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
See the strongest relationship patterns around the current topic before diving into the raw triples.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
effects side disease treatment patients pregnancy hyperprolactinemia used ergot also parkinson's use may lactation dostinex derivatives dopamine agonist frequent drug
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Cabergoline | 3D model (JSmol) | Interactive image | 1.00 | infobox |
| Cabergoline | AHFS/Drugs.com | Monograph | 1.00 | infobox |
| Cabergoline | ATC code | G02CB03 (WHO) N04BC06 (WHO) | 1.00 | infobox |
| Cabergoline | Bioavailability | 50–80% | 1.00 | infobox |
| Cabergoline | CAS Number | 81409-90-7 Y | 1.00 | infobox |
| Cabergoline | ChEBI | CHEBI:3286 Y | 1.00 | infobox |
| Cabergoline | ChEMBL | ChEMBL1201087 N | 1.00 | infobox |
| Cabergoline | ChemSpider | 49452 Y | 1.00 | infobox |
| Cabergoline | CompTox Dashboard (EPA) | DTXSID6022719 | 1.00 | infobox |
| Cabergoline | DrugBank | DB00248 Y | 1.00 | infobox |
| Cabergoline | ECHA InfoCard | 100.155.380 | 1.00 | infobox |
| Cabergoline | Elimination half-life | 63–69 hours (estimated) | 1.00 | infobox |
| Cabergoline | Excretion | Urine (22%), feces (60%) | 1.00 | infobox |
| Cabergoline | Formula | C26H37N5O2 | 1.00 | infobox |
| Cabergoline | IUPHAR/BPS | 37 | 1.00 | infobox |
| Cabergoline | KEGG | D00987 Y | 1.00 | infobox |
| Cabergoline | Legal status | AU: S4 (Prescription only) | 1.00 | infobox |
| Cabergoline | Legal status | US: ℞-only | 1.00 | infobox |
| Cabergoline | License data | US DailyMed: Cabergoline | 1.00 | infobox |
| Cabergoline | Metabolism | Liver, predominately via hydrolysis of the acylurea bond or the urea moiety | 1.00 | infobox |
| Cabergoline | Molar mass | 451.615 g·mol−1 | 1.00 | infobox |
| Cabergoline | Other names | N-[3-(Dimethylamino)propyl]-N-(ethylcarbamoyl)-6-(prop-2-en-1-yl)ergoline-8β-carboxamide | 1.00 | infobox |
| Cabergoline | Protein binding | Moderately bound (40–42%); concentration-independent | 1.00 | infobox |
| Cabergoline | PubChem CID | 54746 | 1.00 | infobox |
| Cabergoline | Routes of administration | Oral | 1.00 | infobox |
| Cabergoline | Trade names | Dostinex, others | 1.00 | infobox |
| Cabergoline | UNII | LL60K9J05T | 1.00 | infobox |
| Cabergoline | is a | ergot derivative and a potent dopamine D2 receptor agonist.Cabergoline was patented in 1980 and approved for medical use in 1993 | 0.90 | text |
These clusters group vocabulary that occurs around closely connected concepts in the source material.
Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.